ARTL Artelo Biosciences announces results from a nonclinical osteoarthritis study supporting art26.12 as a potential first-in-class new ther

ARTL Artelo Biosciences announces results from a nonclinical osteoarthritis study supporting art26.12 as a potential first-in-class new therapy for chronic pain conditions